Zhejiang Doer Biologics (Doer Bio) has concluded subject enrolment in a Phase Ib/IIa clinical trial of DR10624 in obese patients with modest hypertriglyceridemia in New Zealand.

A long-acting tri-specific agonist, DR10624 is directed at the fibroblast growth factor 21 receptor (FGF21R), glucagon-like peptide-1 receptor (GLP-1R), and glucagon receptor (GCGR).

The placebo-controlled, randomised, double-blind trial will assess the tolerability, safety, pharmacokinetics and pharmacodynamics of DR10624 in adults with a body mass index (BMI) of 30kg/m² to 45kg/m² and modest hypertriglyceridemia.

Four varying doses of DR10624 will be assessed in the trial.

The trial subjects will receive subcutaneous injections of DR10624 once a week or a placebo for 12 weeks.

The impact of DR10624 on serum lipids, liver fat, and body weight will also be assessed in the trial.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Doer Bio founder and CEO Yanshan Huang said: “DR10624 is a novel FIC tri-specific biotherapeutic that specifically agonises FGF21R, GLP-1R, and GCGR. Utilising Doer Bio’s proprietary MultipleBody platform technology, DR10624 is designed and engineered to exhibit balanced activity for various metabolic diseases.

“In our preclinical studies, DR10624 has shown outstanding potency on body weight reduction, blood lipid normalisation, and liver function improvement.”

The company plans to report the data from the clinical trial earlier next year.

Doer Bio chief operating officer Yongliang Fang said: “We’re excited to announce the successful completion of patient enrolment for our Phase Ib/IIa clinical trial of DR10624 in New Zealand. This achievement marks an important milestone in our clinical translation of DR10624 globally.

“There is a growing unmet medical need for patients suffering from obesity and hypertriglyceridemia. We look forward to developing DR10624 as a potential treatment for patients struggling with metabolic dysfunction.”